<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01517893</url>
  </required_header>
  <id_info>
    <org_study_id>UM-DERM001</org_study_id>
    <nct_id>NCT01517893</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Simvastatin to Treat Generalized Vitiligo</brief_title>
  <official_title>A Phase-II, Randomized, Placebo-controlled Trial of Simvastatin in Generalized Vitiligo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Harris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators purpose is to initiate a phase II, randomized, placebo-controlled clinical
      trial to test simvastatin, an FDA-approved medication for hypercholesterolemia, as a new
      treatment for vitiligo. The aims of this placebo-controlled study seek to determine the
      safety and potential efficacy of simvastatin 80mg daily versus placebo in adult male patients
      with generalized vitiligo. Additionally, the investigators will collect blood to examine the
      effect of simvastatin on autoreactive CD8+ T cells in vitiligo patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitiligo is an autoimmune disease caused by autoreactive CD8+ T lymphocytes that target
      melanocytes, and interferon-γ-induced CXCL10 plays an important role.1 Simvastatin inhibits
      interferon-γ signaling by blocking activation of STAT12 and prevented and reversed disease in
      our mouse model.3 A case report described a patient with vitiligo who repigmented with
      simvastatin.4 We conducted a small, randomized, double-blind, placebo-controlled, phase II
      clinical trial to test simvastatin as a treatment for vitiligo. After obtaining informed
      consent, we enrolled men ages 18 to 64 years with vitiligo affecting 3% to 50% of their body
      surface area (BSA). We excluded patients with a segmental presentation; those already taking
      3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor; those with existing thyroid
      disease; and women, based on their increased risk of simvastatin-induced myopathy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Decrease in Vitiligo Area Scoring Index (VASI) Score</measure>
    <time_frame>Assessed at baseline and final study visit, 6 months after randomization</time_frame>
    <description>Number of participants with 33% decrease in the Vitiligo Area Scoring Index (VASI) from baseline to the last available study visit.
Decrease in VASI score means improvement. Minimum value is 0, that means no vitiligo. maximum value is 100, that means 100% of the body surface area has vitiligo (total body surface area).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Increase in Investigator's Global Assessment Score</measure>
    <time_frame>Assessed at baseline and final study visit, 6 months after randomization</time_frame>
    <description>Increase in Investigator Global Assessment Scores of 30% or more from baseline to last available visit.
Increase in score means improvement. 0% is no improvement at all. 100% is complete recovery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Toxicity From of High-dose Simvastatin .</measure>
    <time_frame>Assessed at baseline, then monthly until final study visit, six months after randomization.</time_frame>
    <description>The number of participants who experienced toxicity based upon monitored lab values (Liver Function Test) and patient symptoms for evidence of simvastatin toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sentinel Patch Area</measure>
    <time_frame>Assessed at baseline and final study visit, 6 months after randomization</time_frame>
    <description>Change in percent depigmentation of sentinel patch lesion from baseline to last available study visit ( 6 months after randomization).
positive numbers mean increase or worsening of sentinel patch area negative numbers mean decrease or improvement of sentinel patch area</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Score by Using DERMATOLOGY LIFE QUALITY INDEX (DLQI)</measure>
    <time_frame>Assessed at baseline and final study visit, 6 months after randomization</time_frame>
    <description>The aim of this questionnaire is to measure how much your skin problem has affected your life. We measured change in questionnaire score from baseline to end of study (at 6 months after randomization) of subjects randomized to treatment with simvastatin versus placebo. Change was measured as a drop in score at the end of 6 months of treatment.
Minimum score is 0, maximum is 30. Higher value means worse score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Increase in Patient's Global Assessment Score</measure>
    <time_frame>Assessed at baseline and final study visit, 6 months after randomization</time_frame>
    <description>Increase in Patient's Global Assessment Scores of 30% or more from baseline to last available visit Increase means improvement. minimum is 0% and maximum is 100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum CXCL10 Levels From the First and Last Available Clinic Visits Were Measured Via ELISA</measure>
    <time_frame>Assessed at baseline and final study visit, 6 months after randomization</time_frame>
    <description>Determination of the effects of simvastatin treatment on Serum CXCL10 levels from the first and last available clinic visits were measured via ELISA in the blood of patients with vitiligo treated with simvastatin versus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CXCR3 Expression on CD8+ T Cells</measure>
    <time_frame>Assessed prior to treatment and periodically while on treatment</time_frame>
    <description>Determination of the effects of simvastatin treatment on CXCR3 expression in melanocyte-specific, autoreactive CD8+ T cells in the blood of patients with vitiligo treated with simvastatin versus placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Vitiligo</condition>
  <arm_group>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sig: Simvastatin 40 mg, increased to 80 mg after 1 month if initial dose tolerated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
    <arm_group_label>Intervention arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male gender

          -  ages 18-64

          -  at least one vitiligo skin lesion measuring at least 2x2 cm in size

          -  willing and able to understand and sign informed consent

          -  able to complete study and comply with study procedures

        Exclusion Criteria:

          -  history of segmental vitiligo

          -  allergy to statin medications

          -  use of statin medications due to cardiac risks.

          -  use of any medications contraindicated with use of simvastatin

          -  use of topical vitiligo treatments in past 4 weeks

          -  use of laser or light-based vitiligo treatments within the past 8 weeks

          -  treatment with immunomodulating oral medications in the past 4 weeks

          -  use of statin medications in the past 8 weeks

          -  evidence of hepatic dysfunction, personal or family history of non-alcoholic steatotic
             hepatitis, or personal history of hepatitis

          -  evidence of renal dysfunction

          -  history of myopathy or rhabdomyolysis, or elevated baseline creatinine kinase

          -  recent history of alcohol or drug abuse

          -  history of diabetes

          -  untreated hypothyroidism

          -  other conditions that require the use of interfering topical or systemic therapy

          -  other current conditions that might interfere with study assessments such as, but not
             limited to, atopic dermatitis and psoriasis

          -  clinically significant abnormal findings or conditions which might, in the opinion of
             the Principal Investigator, interfere with study evaluations or pose a risk to subject
             safety during the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John E. Harris, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Massachusetts, Worcester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Massachusetts Medical School Clinical Research Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>January 13, 2012</study_first_submitted>
  <study_first_submitted_qc>January 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2012</study_first_posted>
  <results_first_submitted>February 19, 2015</results_first_submitted>
  <results_first_submitted_qc>March 10, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 12, 2015</results_first_posted>
  <last_update_submitted>October 17, 2018</last_update_submitted>
  <last_update_submitted_qc>October 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>John Harris</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>vitiligo</keyword>
  <keyword>simvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intervention Arm</title>
          <description>Sig: Simvastatin 40 mg, increased to 80 mg after 1 month if initial dose tolerated
Simvastatin: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
        </group>
        <group group_id="P2">
          <title>Placebo Arm</title>
          <description>Placebo: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention Arm</title>
          <description>Sig: Simvastatin 40 mg, increased to 80 mg after 1 month if initial dose tolerated
Simvastatin: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
        </group>
        <group group_id="B2">
          <title>Placebo Arm</title>
          <description>Placebo: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.9" lower_limit="28" upper_limit="55"/>
                    <measurement group_id="B2" value="39" lower_limit="32" upper_limit="49"/>
                    <measurement group_id="B3" value="41.6" lower_limit="28" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vitiligo area scoring index</title>
          <description>The vitiligo area scoring index (VASI) is a measure of the surface area affected by vitiligo in a given research subject. It ranges from 0% (no vitiligo) to 100% (complete depigmentation of the entire body surface area). In terms of treatment, a decrease in VASI is desirable as it indicates less surface area affected by vitiligo. The score represents an estimate made by the investigators, based on the approximation that one &quot;hand unit,&quot; is roughly equivalent to 1% of the body surface area.</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.81" lower_limit="3.23" upper_limit="40.93"/>
                    <measurement group_id="B2" value="23.09" lower_limit="5.12" upper_limit="46.26"/>
                    <measurement group_id="B3" value="19.23" lower_limit="3.23" upper_limit="46.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Decrease in Vitiligo Area Scoring Index (VASI) Score</title>
        <description>Number of participants with 33% decrease in the Vitiligo Area Scoring Index (VASI) from baseline to the last available study visit.
Decrease in VASI score means improvement. Minimum value is 0, that means no vitiligo. maximum value is 100, that means 100% of the body surface area has vitiligo (total body surface area).</description>
        <time_frame>Assessed at baseline and final study visit, 6 months after randomization</time_frame>
        <population>Overall number of participants for intervention (5) differs from enrollment (8) due to withdraw of 3 participants on intervention arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Sig: Simvastatin 40 mg, increased to 80 mg after 1 month if initial dose tolerated
Simvastatin: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Placebo: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Decrease in Vitiligo Area Scoring Index (VASI) Score</title>
          <description>Number of participants with 33% decrease in the Vitiligo Area Scoring Index (VASI) from baseline to the last available study visit.
Decrease in VASI score means improvement. Minimum value is 0, that means no vitiligo. maximum value is 100, that means 100% of the body surface area has vitiligo (total body surface area).</description>
          <population>Overall number of participants for intervention (5) differs from enrollment (8) due to withdraw of 3 participants on intervention arm.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Increase in Investigator's Global Assessment Score</title>
        <description>Increase in Investigator Global Assessment Scores of 30% or more from baseline to last available visit.
Increase in score means improvement. 0% is no improvement at all. 100% is complete recovery.</description>
        <time_frame>Assessed at baseline and final study visit, 6 months after randomization</time_frame>
        <population>For placebo arm, only 6 out of 7 participants reported data.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Sig: Simvastatin 40 mg, increased to 80 mg after 1 month if initial dose tolerated
Simvastatin: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Placebo: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Increase in Investigator's Global Assessment Score</title>
          <description>Increase in Investigator Global Assessment Scores of 30% or more from baseline to last available visit.
Increase in score means improvement. 0% is no improvement at all. 100% is complete recovery.</description>
          <population>For placebo arm, only 6 out of 7 participants reported data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Toxicity From of High-dose Simvastatin .</title>
        <description>The number of participants who experienced toxicity based upon monitored lab values (Liver Function Test) and patient symptoms for evidence of simvastatin toxicity</description>
        <time_frame>Assessed at baseline, then monthly until final study visit, six months after randomization.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Sig: Simvastatin 40 mg, increased to 80 mg after 1 month if initial dose tolerated
Simvastatin: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Placebo: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Toxicity From of High-dose Simvastatin .</title>
          <description>The number of participants who experienced toxicity based upon monitored lab values (Liver Function Test) and patient symptoms for evidence of simvastatin toxicity</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sentinel Patch Area</title>
        <description>Change in percent depigmentation of sentinel patch lesion from baseline to last available study visit ( 6 months after randomization).
positive numbers mean increase or worsening of sentinel patch area negative numbers mean decrease or improvement of sentinel patch area</description>
        <time_frame>Assessed at baseline and final study visit, 6 months after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Sig: Simvastatin 40 mg, increased to 80 mg after 1 month if initial dose tolerated
Simvastatin: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Placebo: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sentinel Patch Area</title>
          <description>Change in percent depigmentation of sentinel patch lesion from baseline to last available study visit ( 6 months after randomization).
positive numbers mean increase or worsening of sentinel patch area negative numbers mean decrease or improvement of sentinel patch area</description>
          <units>cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2272" spread="3.463"/>
                    <measurement group_id="O2" value="3.8571" spread="9.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life Score by Using DERMATOLOGY LIFE QUALITY INDEX (DLQI)</title>
        <description>The aim of this questionnaire is to measure how much your skin problem has affected your life. We measured change in questionnaire score from baseline to end of study (at 6 months after randomization) of subjects randomized to treatment with simvastatin versus placebo. Change was measured as a drop in score at the end of 6 months of treatment.
Minimum score is 0, maximum is 30. Higher value means worse score.</description>
        <time_frame>Assessed at baseline and final study visit, 6 months after randomization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Sig: Simvastatin 40 mg, increased to 80 mg after 1 month if initial dose tolerated
Simvastatin: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Placebo: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life Score by Using DERMATOLOGY LIFE QUALITY INDEX (DLQI)</title>
          <description>The aim of this questionnaire is to measure how much your skin problem has affected your life. We measured change in questionnaire score from baseline to end of study (at 6 months after randomization) of subjects randomized to treatment with simvastatin versus placebo. Change was measured as a drop in score at the end of 6 months of treatment.
Minimum score is 0, maximum is 30. Higher value means worse score.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="4.159326869"/>
                    <measurement group_id="O2" value="2.285714286" spread="2.690370837"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Increase in Patient's Global Assessment Score</title>
        <description>Increase in Patient's Global Assessment Scores of 30% or more from baseline to last available visit Increase means improvement. minimum is 0% and maximum is 100%</description>
        <time_frame>Assessed at baseline and final study visit, 6 months after randomization</time_frame>
        <population>Placebo arm reports 6 instead of enrolled 7 due to failure of participant to complete assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Sig: Simvastatin 40 mg, increased to 80 mg after 1 month if initial dose tolerated
Simvastatin: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Placebo: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Increase in Patient's Global Assessment Score</title>
          <description>Increase in Patient's Global Assessment Scores of 30% or more from baseline to last available visit Increase means improvement. minimum is 0% and maximum is 100%</description>
          <population>Placebo arm reports 6 instead of enrolled 7 due to failure of participant to complete assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum CXCL10 Levels From the First and Last Available Clinic Visits Were Measured Via ELISA</title>
        <description>Determination of the effects of simvastatin treatment on Serum CXCL10 levels from the first and last available clinic visits were measured via ELISA in the blood of patients with vitiligo treated with simvastatin versus placebo</description>
        <time_frame>Assessed at baseline and final study visit, 6 months after randomization</time_frame>
        <population>Serum CXCL10 levels from the first and last available clinic visits were measured via ELISA. The mean and SEM are reported here. One participant in intervention group was not included because participant withdrew before a second CXCL10 level was obtained. Other withdrawn participants were included, using the CXCL10 from their final visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Sig: Simvastatin 40 mg, increased to 80 mg after 1 month if initial dose tolerated
Simvastatin: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Placebo: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>Serum CXCL10 Levels From the First and Last Available Clinic Visits Were Measured Via ELISA</title>
          <description>Determination of the effects of simvastatin treatment on Serum CXCL10 levels from the first and last available clinic visits were measured via ELISA in the blood of patients with vitiligo treated with simvastatin versus placebo</description>
          <population>Serum CXCL10 levels from the first and last available clinic visits were measured via ELISA. The mean and SEM are reported here. One participant in intervention group was not included because participant withdrew before a second CXCL10 level was obtained. Other withdrawn participants were included, using the CXCL10 from their final visits.</population>
          <units>Fold change of baseline CXCL10 level</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9148" spread="0.263"/>
                    <measurement group_id="O2" value="0.6176" spread="0.1685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CXCR3 Expression on CD8+ T Cells</title>
        <description>Determination of the effects of simvastatin treatment on CXCR3 expression in melanocyte-specific, autoreactive CD8+ T cells in the blood of patients with vitiligo treated with simvastatin versus placebo</description>
        <time_frame>Assessed prior to treatment and periodically while on treatment</time_frame>
        <population>No data collected as this outcome was abandoned due to budget constraints and strength of other study results.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Arm</title>
            <description>Sig: Simvastatin 40 mg, increased to 80 mg after 1 month if initial dose tolerated
Simvastatin: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Placebo: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
          </group>
        </group_list>
        <measure>
          <title>CXCR3 Expression on CD8+ T Cells</title>
          <description>Determination of the effects of simvastatin treatment on CXCR3 expression in melanocyte-specific, autoreactive CD8+ T cells in the blood of patients with vitiligo treated with simvastatin versus placebo</description>
          <population>No data collected as this outcome was abandoned due to budget constraints and strength of other study results.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months (baseline to end of treatment)</time_frame>
      <desc>Safety lab values and questionnaires collected for outcomes.</desc>
      <group_list>
        <group group_id="E1">
          <title>Intervention Arm</title>
          <description>Sig: Simvastatin 40 mg, increased to 80 mg after 1 month if initial dose tolerated
Simvastatin: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
        </group>
        <group group_id="E2">
          <title>Placebo Arm</title>
          <description>Placebo: Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Burn</sub_title>
                <description>Sustained at work, unrelated</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>stool odor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>dental infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>leg twinge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>pulled muscle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>arthrlagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>sleep disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urine color change</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>URI symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>xerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The following outcome measures were abandoned: 1.Decrease in CXCR3 exp. on CD8 positive T-Cells, 2.Corr. Among Var. Outcome Measures for Vitiligo: procedures not performed/no data collected due to strength of prior outcomes &amp; budget limitation.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>John E. Harris, MD, PhD</name_or_title>
      <organization>University of Massachusetts Medical School</organization>
      <phone>508-856-1982</phone>
      <email>john.harris@umassmed.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

